Brokerages expect Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Rating) to post earnings of ($0.07) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics reported earnings per share of ($0.14) during the same quarter last year, which suggests a positive year-over-year growth rate of 50%. The firm is expected to report its next earnings report on Monday, January 1st.
On average, analysts expect that Soleno Therapeutics will report full-year earnings of ($0.28) per share for the current year. For the next year, analysts expect that the business will report earnings of ($0.20) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Soleno Therapeutics.
Soleno Therapeutics (NASDAQ:SLNO – Get Rating) last announced its quarterly earnings data on Thursday, March 31st. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08).
A number of institutional investors and hedge funds have recently bought and sold shares of SLNO. Renaissance Technologies LLC raised its holdings in Soleno Therapeutics by 482.7% in the fourth quarter. Renaissance Technologies LLC now owns 60,600 shares of the company’s stock worth $25,000 after purchasing an additional 50,200 shares during the period. BlackRock Inc. raised its holdings in Soleno Therapeutics by 868.8% in the third quarter. BlackRock Inc. now owns 129,773 shares of the company’s stock worth $120,000 after purchasing an additional 116,378 shares during the period. Millennium Management LLC bought a new stake in shares of Soleno Therapeutics during the second quarter worth $222,000. Two Sigma Investments LP increased its position in shares of Soleno Therapeutics by 67.6% during the third quarter. Two Sigma Investments LP now owns 365,846 shares of the company’s stock worth $338,000 after acquiring an additional 147,594 shares in the last quarter. Finally, Granite Point Capital Management L.P. increased its position in shares of Soleno Therapeutics by 20.7% during the fourth quarter. Granite Point Capital Management L.P. now owns 846,850 shares of the company’s stock worth $347,000 after acquiring an additional 145,012 shares in the last quarter. Institutional investors own 69.49% of the company’s stock.
Shares of NASDAQ SLNO opened at $0.18 on Tuesday. The company’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.41. Soleno Therapeutics has a fifty-two week low of $0.13 and a fifty-two week high of $1.67. The firm has a market capitalization of $14.18 million, a P/E ratio of -0.51 and a beta of 0.42.
About Soleno Therapeutics (Get Rating)
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program.
- Get a free copy of the StockNews.com research report on Soleno Therapeutics (SLNO)
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Option Care Health Stock is Making a Healthy Pullback
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.